Transmembrane Domain-induced Oligomerization Is Crucial for the Functions of Syndecan-2 and Syndecan-4*

Received for publication, August 22, 2005 Published, JBC Papers in Press, October 27, 2005, DOI 10.1074/jbc.M509238200

Sungmun Choi†1, Eunjung Lee†1, Soojin Kwon§, Haein Park‡, Jae Youn Yi‡, Seungin Kim†, Inn-Oc Han§, Yungdae Yun§, and Eok-Soo Oh‡2

From the †Department of Life Sciences, Division of Molecular Life Sciences and Center for Cell Signaling Research, Ewha Womans University, Seoul 120-750, Korea and the §College of Medicine, Department of Physiology and Biophysics, Inha University, Incheon 402-751, Korea

The syndecans are known to form homologous oligomers that may be important for their functions. We have therefore determined the role of oligomerization of syndecan-2 and syndecan-4. A series of glutathione S-transferase-syndecan-2 and syndecan-4 chimeric proteins showed that all syndecan constructs containing the transmembrane domain formed SDS-resistant dimers, but not those lacking it. SDS-resistant dimer formation was hardly seen in the syndecan chimeras where each transmembrane domain was substituted with that of platelet-derived growth factor receptor (PDGFR). Increased MAPK activity was detected in HEK293T cells transfected with syndecan/PDGFR chimeras in a syndecan transmembrane domain-dependent fashion. The chimera-induced MAPK activation was independent of both ligand and extracellular domain, implying that the transmembrane domain is sufficient to induce dimerization/oligomerization in vivo. Furthermore, the syndecan chimeras were defective in syndecan-4-mediated focal adhesion formation and protein kinase Ca activation or in syndecan-2-mediated cell migration. Taken together, these data suggest that the transmembrane domains are sufficient for inducing dimerization and that transmembrane domain-induced oligomerization is crucial for syndecan-2 and syndecan-4 functions.

It is common that signaling through cell surface receptor proteins containing a single transmembrane domain is transduced by noncovalent dimerization of the proteins in response to ligand binding (9, 10). In the case of the platelet-derived growth factor (PDGF) receptor (PDGFR), ligand stimulation of the PDGFR leads to receptor dimerization, activation of the kinase activity of the receptor, and phosphorylation of the receptor at numerous intracellular tyrosine residues. Subsequently, various molecules containing Src homology domains are recruited to the PDGFR where they act as signaling enzymes and adapter molecules (11, 12).

The possible participation of syndecans in signaling was first suggested by the findings that syndecan-4 is a component of focal adhesions (13), where extracellular matrix-induced signal transduction takes place (6–8). When plated on fibronectin, syndecan-4 on the cell surface becomes clustered, and the clustered syndecan-4 interacts with both protein kinase Ca (PKCa) and phosphatidylinositol 4,5-bisphosphate (PIP2) to further transduce downstream signals for focal adhesion and stress fiber formation (14–18). Like growth factor receptors, oligomerization is probably a major step for syndecan-4-mediated signal transduction (6–8). Therefore, the oligomerization status of syndecan-4 is a key important issue, but many of details remain unknown. Several lines of evidence clearly show that the syndecan family has a propensity to oligomerize. All members of this family form homologous dimers or multimers that are resistant to treatment with SDS (2, 19). Asundi and Carey (19) have shown that recombinant syndecan-3 core protein forms stable, noncovalent multimer complexes, and this property requires the presence of the transmembrane domain and a short sequence in the ectodomain flanking region. Similarly, recombinant syndecan-2 and syndecan-4 core proteins form SDS-resistant oligomers even in the complete absence of the cytoplasmic domain (14), implying that the cytoplasmic domains of syndecan-2 and syndecan-4 are not essential for basal oligomerization. All of these studies indicate the importance of the transmembrane domain for syndecan dimerization. However, the relationship between dimerization and function is unclear. In this study we demonstrate that the transmembrane domains are sufficient for SDS-resistant dimerization in vitro and functional dimer formation in vivo and that transmembrane domain-induced oligomerization is crucial for functions of syndecan-2 and syndecan-4.

EXPERIMENTAL PROCEDURES

Materials and Antibodies—Monoclonal anti-phosphorytrosine, anti-phospho-Erk2, anti-syntenin, and anti-Myc antibodies and polyclonal

---

*This work was supported in part by Korea Research Foundation Grant KRF-99-042-D00096, KRF-2002-C03327 (to E.-S. O) and in part by Korea Science and Engineering Foundation (KOSEF) through the Center for Cell Signaling Research at Ewha Womans University. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

†These authors contributed equally to this study and were supported by a fellowship from the Brain Korea 21 project.

‡To whom correspondence should be addressed: Center for Cell Signaling Research, Ewha Womans University, Daehyun-dong, Seodaemun-Gu, Seoul 120-750 Korea. Tel.: 82-2-3277-3761; Fax: 82-2-3277-3760; E-mail: OhES@ewha.ac.kr.

§These authors contributed equally to this study and were supported by a fellowship from the Brain Korea 21 project.

1 The abbreviations used are: PDGF, platelet-derived growth factor; PDGFR, platelet derived growth factor receptor; Erk, extracellular signal-regulated kinase; GST, glutathione S-transferase; HA, hemagglutinin; PIP2, phosphatidylinositol 4,5-bisphosphate; MAPK, mitogen-activate protein kinase; PBS, phosphate-buffered saline; PKCa, protein kinase Ca; REF, rat embryo fibroblast.

2 The abbreviations used are: PDGF, platelet-derived growth factor; PDGFR, platelet derived growth factor receptor; Erk, extracellular signal-regulated kinase; GST, glutathione S-transferase; HA, hemagglutinin; PIP2, phosphatidylinositol 4,5-bisphosphate; MAPK, mitogen-activate protein kinase; PBS, phosphate-buffered saline; PKCa, protein kinase Ca; REF, rat embryo fibroblast.
Transmembrane Domain-induced Oligomerization of Syndecan

anti-Erk2 and anti-vinculin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), and monoclonal anti-PDGFR and anti-PKCα antibodies were from BD Transduction Laboratories. Polyclonal anti-HA antibody was obtained from Cell Signaling (Beverly, MA). PDGF and monoclonal anti-paxillin antibody were purchased from Upstate Biotechnology, Inc (Lake Placid, NY). Anti-syndecan-4 and anti-syndecan-2 antibodies were a gift of Drs. J.R. Couchman (Imperial College London) and A. Woods (University of Alabama at Birmingham). Glutathione-agarose beads were purchased from Amersham Biosciences, reduced glutathione came from Janssen Chemicals (New Brunswick, NJ), and Effectene was from Qiagen (Hilden, Germany). Isopropyl-β-D-thiogalactopyranoside and other chemicals were purchased from Sigma.

Cell Culture and Treatment—HEK293T were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum. A rat small intestinal epithelial cell line (RIE1) was maintained in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine serum. Rat embryo fibroblast (REF) cells were maintained in α-modified Eagle’s medium (Invitrogen) supplemented with 5% fetal bovine serum. For treatment with PDGF, HEK293T cells were starved for 12 h in serum-free media (SFM), and 50 ng/ml PDGF was then added for 15 min.

Expression and Purification of Recombinant Glutathione S-Transferase (GST)-Syndecan-2 and GST-Syndecan-4 Core Proteins—Syndecan-2 and syndecan-4 cDNAs encoding full-length (2E, 4W), the extracellular and the transmembrane domain (2ET, 4ET), the extracellular domain (2E, 4E), the transmembrane domain (2T, 4T), the cytoplasmic domain (2C, 4C), and the transmembrane domain containing four flanking extracellular amino acid residue (KRTE, ERT; single letter amino acid codes) in the extracellular domain either in the absence (2E, 4E) or presence (2ETC, 4ETC) of the cytoplasmic domain were synthesized by PCR and subcloned into GST expression vector pGEX-5X-1 (Amersham Biosciences). Site-directed mutations were generated by PCR amplification (Stratagene, La Jolla, CA). Introduction of the mutations was confirmed by DNA sequence analysis of the plasmids. TABLE ONE lists the oligonucleotides that were used as PCR primers for cloning, and the TABLE ONE legend explains the oligonucleotide names (such as 4W, 2W, etc.) that are used here and throughout. These constructs were used to transform Escherichia coli DH5α, and the expressions of fusion proteins, the GST-syndecan mutants, were induced with 1 mM isopropyl-β-D-thiogalactopyranoside for 7 h. The fusion proteins were purified with glutathione-agarose beads as described previously (14).

Construction of Expression Vectors and Transfection—2ET/PC and 4ET/PC chimeras were constructed by linking the extracellular domain and transmembrane domain (amino acids 1–178 and 1–174) of rat syndecan-2/syndecan-4 and the cytoplasmic domain of human PDGFR (amino acids 557–1107). 2ET/PC and 4ET/PC chimeras were constructed by linking the extracellular domain (amino acids 1–154 and 1–150) and cytoplasmic domain (amino acids 178–209 and 174–202) of rat syndecan-2/syndecan-4 and the transmembrane domain of human PDGFR (amino acids 531–556). The LET/PC chimera was constructed by linking the extracellular domain and transmembrane domain (amino acids 1–27) of LAT (linker for activation of T cells) and the cytoplasmic domain (amino acids 557–1107) of PDGFR. The PE/4T/PC chimera was constructed by linking the extracellular domain (amino acids 1–531) of PDGFR, the transmembrane domain (amino acids 150–174) of syndecan-4, and the cytoplasmic domain (amino acids 557–1107) of PDGFR. The chimeras, and full-length syndecan-2/syndecan-4 constructs were inserted into the HA tagging pcDNA3 expression vector (Invitrogen). HEK293T cells (6 × 10^5) were plated on 6-cm-diameter culture dishes, incubated at 37 °C for 24 h, and then cotransfected with 1 µg of either 2ET/PC, 4ET/PC, LET/PC, PE/4T/PC, 2W, 4W, or HA-pcDNA3 cDNAs and 1 µg of HA-Erk1 cDNA in Effectene reagents (Qiagen). REFS were transfected with either 4W or 4E/PT/4C using Effectene reagents, and these cells were selected by G418 (500 µg/ml) for 3 weeks. RIE1 cells were transfected with either 2W or 2E/PT/2C using PolyFect reagents (Qiagen).

Lysate Preparation and Immunoblotting—After cultures were washed twice with PBS, the cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 0.5 mM EDTA, 10 mM NaF, and 2 mM Na3VO4) containing a protease inhibitor mixture (1 µg/ml aprotinin, 1 µg/ml antipain, 5 µg/ml leupeptin, 1 µg/ml pepstatin A, and 20 µg/ml phenylmethylsulfonyl fluoride). Cell lysates were clarified by centrifugation at 13,000 rpm for 15 min at 4 °C, denatured with SDS-PAGE sample buffer, boiled, and analyzed by SDS-PAGE. Proteins were transferred onto polyvinylidene difluoride membranes (Amersham Biosciences) and probed with appropriate antibodies, followed by species-specific, horseradish peroxidase-conjugated secondary antibodies. Signals were detected by enhanced chemiluminescence (ECL; Amersham Biosciences).

Cell Adhesion Assay—35-mm culture plates were coated with either 20 µg/ml syndecan-2 or syndecan-4 antibody in PBS overnight at 4 °C. Each antibody-coated plate was washed with PBS, blocked with 0.2% heat-inactivated bovine serum albumin for 1 h at room temperature, and then washed again with PBS (3 × 5 min). HEK293T cells were detached with 0.05% trypsin suspended in serum-free media containing 0.25 mg/ml soybean trypsin inhibitor and centrifuged. Cells were resuspended in 10% Dulbecco’s modified Eagle’s medium, plated on the coated plates, and incubated at 37 °C.

Microscopic Analysis—Cells were seeded onto glass coverslips at a density of 4 × 10^4 cells, incubated for 24 h, and then fixed with 3.5% paraformaldehyde in PBS at room temperature for 10 min. After rinsing three times with PBS, cells were permeabilized with 0.5% Triton X-100 in PBS at room temperature for 10 min and blocked with 0.05% bovine serum albumin and 0.05% gelatin in PBS for 1 h. After being washed, cells were stained with the specific antibodies. Images were obtained by digital imaging florescence microscopy using a charge-coupled device camera (Carl Zeiss).

In Vitro PKC Activity Assay—The standard reaction mixture (total 20 µl) contained 50 mM HEPES (pH 7.2), 3 mM magnesium acetate, PKCα (Upstate Biotechnology), and 1 µg of 50 mM HEPES histone III-S as a substrate. PIP2 (50 mM) and 4W, 4E/PT/4C, 4Tc, and PT/4C (0.25 mg/ml) were added as indicated. Reactions were started by the addition of 200 µM ATP (0.5 µCi of [γ-32P]ATP). After incubation at 25 °C for 5 min, the reaction was stopped by adding SDS-PAGE sample buffer and heating to 95 °C for 5 min. Proteins were separated by electrophoresis on 12% SDS-polyacrylamide gels, and phosphorylated histone III-S was detected by autoradiograph and quantified by Image Reader BAS-2500 (Fujiﬁlm) imaging densitometer.

GST Pull Down Assays—Recombinant GST-syndecan-4 proteins were purified on glutathione-agarose beads as described previously (14, 15). Proteins bound on the bead were washed three times with lysis buffer and mixed with either REF cell lysate (Fig. 6C) or purified PKCα (20) (Fig. 6D). After incubation at 4 °C on a rotator for 2 h, the precipitated complex was eluted with SDS-PAGE sample buffer, resolved by SDS-PAGE, and immunoblotted with the specific antibody.

Migration Assay—Gelatin (1 µg/ml in PBS) was added to each well of a Transwell plate (8-µm pore size; Costar, Cambridge, MA), and the
### TABLE ONE

**Oligonucleotides used as PCR primers**

Sequences of the oligonucleotides are listed from the 5'-end. Underlined positions indicate restriction enzyme sites used for cloning. W, wild type; E, extracellular domain, T, transmembrane domain; e, ectodomain flanking region; C, cytoplasmic domain; 2, syndecan-2; 4, syndecan-4, P, PDGFR; L, LAT.

| Name | Syndecan-4 constructs | Sense sequence | Antisense sequence |
|------|-----------------------|----------------|-------------------|
| 4W   | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4W   | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |
| 4ET  | Syndecan-4 constructs | 5'-CTGTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 4ET  | Syndecan-4 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-TGGGACTCGAGTGCATAAAACTC-3' |

| Name | Syndecan-2 constructs | Sense sequence | Antisense sequence |
|------|-----------------------|----------------|-------------------|
| 2W   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2W   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |
| 2E   | Syndecan-2 constructs | 5'-GGCTTGAATTCATGGCGCCTGTC-3' | 5'-AAGAATCGAGAATGCGAGTG-3' |

| Name | PDGFR constructs | Sense sequence | Antisense sequence |
|------|----------------|----------------|-------------------|
| PE   | PDGFR constructs | 5'-GCAAATATCATTCCGCTCTG-3' | 5'-ATCGGTTACATCTTTAAGGAG-3' |
| PT   | PDGFR constructs | 5'-TTTGTATACATCGTGATCATCTG-3' | 5'-ATCGGTTACATCTTTAAGGAG-3' |
| PC   | PDGFR constructs | 5'-TAAATATCATTCCGCTCTG-3' | 5'-ATCGGTTACATCTTTAAGGAG-3' |

| Name | LAT constructs | Sense sequence | Antisense sequence |
|------|----------------|----------------|-------------------|
| LET  | LAT constructs | 5'-ATACGGAATTTCATGGGAGGGCC-3' | 5'-GCGGCGCGCAACAGCATGTCCAT-3' |
Transmembrane Domain-induced Oligomerization of Syndecan

To further investigate the function of the transmembrane domain, each transmembrane domain of syndecan-2 and syndecan-4 was replaced with the transmembrane domain of PDGFR that contains a single transmembrane domain and forms noncovalent dimers in response to ligand binding (9, 10). Consistently, GST-4W and GST-2W showed a strong SDS-resistant dimer formation that was hardly seen in 4E/4T/4C (Fig. 4A) and 2E/2T/2C (Fig. 4B). Furthermore, mutants PE/4T and PE/4TC, which contained the transmembrane domain of syndecan but not that of PDGFR, showed SDS-resistant dimer formation (Fig. 3C). Therefore, these data strongly suggest that the transmembrane domain is sufficient for inducing SDS-resistant dimerization of both syndecan-2 and syndecan-4 core proteins.

Transmembrane Domains Are Sufficient for Inducing Dimer Formation of Chimeric Proteins in Vivo—Additional syndecan chimeras (4ET/PC and 2ET/PC) were constructed that consisted of the extracellular domain and transmembrane domain of each syndecan and the cytoplasmic domain of PDGFR. Either 4ET/PC or 2ET/PC chimera cDNA was cotransfected with Erk1 cDNA into HEK293T cells, and chimera-induced MAPK activation was analyzed. Because it is well known that dimerization of PDGFR cytoplasmic domain is sufficient to activate MAPK activity (11, 12), MAPK activation indicates dimerization of these chimeras. Western blotting with anti-phospho-Erk antibody showed that MAPK activation in chimera-transfected cells was increased compared with that in vector-transfected cells (Fig. 4A, bottom section) together with increased tyrosine phosphorylation of several proteins (Fig. 4A, top section). In contrast, transfection of wild type syndecan-4, wild type syndecan-2, or the syndecan-4 chimera with Gly to Leu substitution in the transmembrane domain cDNAs did not affect MAPK activity (Fig. 4B). Interestingly, there was no significant difference in MAPK activation between 4ET/PC and 2ET/PC (Fig. 4B), implying that both transmembrane domains similarly induceimerization of chimeras. Because overexpression of the PDGFR cytoplasmic

RESULTS

Transmembrane Domains Are Essential for SDS-resistant Dimerization of Syndecan-2 and Syndecan-4 Core Proteins—Several recombinant syndecan-2 and syndecan-4 constructs were expressed as GST fusion proteins (Fig. 1A) that were purified using glutathione-agarose beads and analyzed by SDS-PAGE following Coomassie blue staining (Fig. 1B and C). Consistent with the previous reports (14), recombinant full-length syndecan-4 core protein (GST-4W) resolved as SDS-resistant dimerization. In addition, five different mutants (4ET, 4ETC, 4TC, 4eT, and 4T) that contained the transmembrane domain showed SDS-resistant dimer formation. On the other hand, neither the cytoplasmic domain (4C) nor the extracellular domain alone (4E) showed SDS-resistant dimerization. Syndecan-2 core proteins showed closely similar results to those of syndecan-4 (Fig. 1C). Therefore, it seems that the transmembrane domain is important for SDS-resistant dimerization of syndecan-2 and syndecan-4. Similar to syndecan-3 (19), replacement of conserved glycine residues in the transmembrane domain with leucine residues (Gly → Leu) abolished SDS-resistant dimer formation of both syndecan-2 and syndecan-4 (Fig. 2), supporting the notion that the transmembrane domain is crucial for SDS-resistant dimerization of both syndecan-2 and syndecan-4.

mAlarangents were separated by elec-
trophoresis on 10% SDS-polyacrylamide gels and stained with Coomassie Blue. Molecular mass markers in kilodaltons are shown. Migration positions of SDS-resistant dimer (●●●●) and monomer (●●) are indicated. IPTG, isopropyl-β-d-thiogalactopyranoside.

To further investigate the function of the transmembrane domain, each transmembrane domain of syndecan-2 and syndecan-4 was replaced with the transmembrane domain of PDGFR that contains a single transmembrane domain and forms noncovalent dimers in response to ligand binding (9, 10). Consistently, GST-4W and GST-2W showed a strong SDS-resistant dimer formation that was hardly seen in 4E/4T/4C (Fig. 3A) and 2E/2T/2C (Fig. 3B). Furthermore, mutants PE/4T and PE/4TC, which contained the transmembrane domain of syndecan but not that of PDGFR, showed SDS-resistant dimer formation (Fig. 3C). Therefore, these data strongly suggest that the transmembrane domain is sufficient for inducing SDS-resistant dimerization of both syndecan-2 and syndecan-4 core proteins.

Transmembrane Domains Are Sufficient for Inducing Dimer Formation of Chimeric Proteins in Vivo—Additional syndecan chimeras (4ET/PC and 2ET/PC) were constructed that consisted of the extracellular domain and transmembrane domain of each syndecan and the cytoplasmic domain of PDGFR. Either 4ET/PC or 2ET/PC chimera cDNA was cotransfected with Erk1 cDNA into HEK293T cells, and chimera-induced MAPK activation was analyzed. Because it is well known that dimerization of PDGFR cytoplasmic domain is sufficient to activate MAPK activity (11, 12), MAPK activation indicates dimerization of these chimeras. Western blotting with anti-phospho-Erk antibody showed that MAPK activation in chimera-transfected cells was increased compared with that in vector-transfected cells (Fig. 4A, bottom section) together with increased tyrosine phosphorylation of several proteins (Fig. 4A, top section). In contrast, transfection of wild type syndecan-4, wild type syndecan-2, or the syndecan-4 chimera with Gly to Leu substitution in the transmembrane domain cDNAs did not affect MAPK activity (Fig. 4B). Interestingly, there was no significant difference in MAPK activation between 4ET/PC and 2ET/PC (Fig. 4B), implying that both transmembrane domains similarly induce dimerization of chimeras. Because overexpression of the PDGFR cytoplasmic

mAlarangents were separated by elec-
trophoresis on 10% SDS-polyacrylamide gels and stained with Coomassie Blue. Molecular mass markers in kilodaltons are shown. Migration positions of SDS-resistant dimer (●●●●) and monomer (●●) are indicated. IPTG, isopropyl-β-d-thiogalactopyranoside.

To further investigate the function of the transmembrane domain, each transmembrane domain of syndecan-2 and syndecan-4 was replaced with the transmembrane domain of PDGFR that contains a single transmembrane domain and forms noncovalent dimers in response to ligand binding (9, 10). Consistently, GST-4W and GST-2W showed a strong SDS-resistant dimer formation that was hardly seen in 4E/4T/4C (Fig. 3A) and 2E/2T/2C (Fig. 3B). Furthermore, mutants PE/4T and PE/4TC, which contained the transmembrane domain of syndecan but not that of PDGFR, showed SDS-resistant dimer formation (Fig. 3C). Therefore, these data strongly suggest that the transmembrane domain is sufficient for inducing SDS-resistant dimerization of both syndecan-2 and syndecan-4 core proteins.

Transmembrane Domains Are Sufficient for Inducing Dimer Formation of Chimeric Proteins in Vivo—Additional syndecan chimeras (4ET/PC and 2ET/PC) were constructed that consisted of the extracellular domain and transmembrane domain of each syndecan and the cytoplasmic domain of PDGFR. Either 4ET/PC or 2ET/PC chimera cDNA was cotransfected with Erk1 cDNA into HEK293T cells, and chimera-induced MAPK activation was analyzed. Because it is well known that dimerization of PDGFR cytoplasmic domain is sufficient to activate MAPK activity (11, 12), MAPK activation indicates dimerization of these chimeras. Western blotting with anti-phospho-Erk antibody showed that MAPK activation in chimera-transfected cells was increased compared with that in vector-transfected cells (Fig. 4A, bottom section) together with increased tyrosine phosphorylation of several proteins (Fig. 4A, top section). In contrast, transfection of wild type syndecan-4, wild type syndecan-2, or the syndecan-4 chimera with Gly to Leu substitution in the transmembrane domain cDNAs did not affect MAPK activity (Fig. 4B). Interestingly, there was no significant difference in MAPK activation between 4ET/PC and 2ET/PC (Fig. 4B), implying that both transmembrane domains similarly induce dimerization of chimeras. Because overexpression of the PDGFR cytoplasmic
Transmembrane Domain-induced Oligomerization of Syndecan

Transmembrane Domain-induced Oligomerization Is Crucial for Syndecan Functions—We next investigated the functionality of transmembrane domain-induced oligomerization. Because syndecan-4 plays an important role in focal adhesion formation, we analyzed the effect of the altered oligomerization on focal adhesion formation. REF cells transfected with the cDNAs of either 4W or 4E/PT/4C were plated on either syndecan-2 or syndecan-4 antibody-coated plates to induce clustering of syndecan-2 and syndecan-4 extracellular domains. However, chimera-induced MAPK activities were not affected by engagement of the extracellular domain with the specific antibodies (Fig. 5A). We then made a PDGFR chimera where its transmembrane domain was substituted with that of syndecan-4 (PE/4T/PC) (Fig. 5C, top section), and expressed this chimera in HEK293T cells. The extracellular domain does not affect dimerization tendency of the transmembrane domain. These results strongly suggest that both syndecan-2 and syndecan-4-domains in vivo mediated by their transmembrane domains alone.

Transmembrane Domain-induced Oligomerization Is Crucial for Syndecan Functions—We next investigated the functionality of transmembrane domain-induced oligomerization. Because syndecan-4 plays an important role in focal adhesion formation, we analyzed the effect of the altered oligomerization on focal adhesion formation. REF cells transfected with the cDNAs of either 4W or 4E/PT/4C were plated on fibronectin, and the focal adhesions were highlighted by indirect immu-
Transmembrane Domain-induced Oligomerization of Syndecan

**DISCUSSION**

Syndecan core proteins are known to have propensity to form non-covalently linked dimers (2, 5, 19). High sequence homology and a previous study with syndecan-3 have suggested that both the transmembrane domain and the four amino acid residues in the ectodomain flanking region are important for dimerization of syndecan core proteins. In this study, we have further investigated the importance of each syndecan domain for functional dimerization. Consistent with previous results (14, 19), recombinant full-length core proteins of syndecan-2 and syndecan-4 (GST-4W and GST-2W) showed a strong SDS-resistant dimer formation (Figs. 1–3). It is clear that syndecans form dimers and the transmembrane domains are crucial for SDS-resistant dimerization of both syndecan-2 and syndecan-4 in vitro. However, there is no direct evidence showing transmembrane domain-induced dimer formation of syndecans in vivo. To define functional dimerization of syndecan core protein in cells, several syndecan-PDGFR chimeras have been used. This receptor has been chosen because its activation is dependent on receptor dimeriza-
decan-4 can become a high order oligomer both on the extracellular matrix, form higher order oligomers. Because syndecan-2 and syndecan-4 may form constitutive dimers that, after plating the case in syndecan-mediated cell spreading. Because syndecan-4 has a activation and electrophoretic mobility (Fig. 4 and 5). This result confirms that growth factor receptors form dimers in a ligand-dependent manner. However, the chimeras containing the transmembrane domain of either syndecan-2 or syndecan-4 likely form constitutive dimers, based on MAPK activation and electrophoretic mobility (Fig. 4 and 5). This result confirms the hypothesis that dimerization of PDGF is PDGF-dependent and sufficient for PDGF-mediated MAPK activation. However, it is not the case in syndecan-mediated cell spreading. Because syndecan-4 has a strong tendency for higher order oligomerization (6, 19, 28), both syndecan-2 and syndecan-4 may form constitutive dimers that, after plating on the extracellular matrix, form higher order oligomers. Because syndecan-4 can become a high order oligomer both in vivo and in vitro, we could not exclude the possibility that the chimeric proteins described here might also form higher order oligomers. Under our experimental conditions, MAPK activity only reflects dimerization but not higher order oligomerization. Therefore, we cannot discriminate whether the transmembrane domain induces dimerization or higher order oligomerization of syndecan core protein in vivo. In addition, although neither the extracellular domain nor the cytoplasmic domain promotes SDS-resistant dimerization of syndecans, it may be possible that both domains regulate higher order oligomerization of syndecan core protein in vivo.

Syndecan-4 acts as a coreceptor with integrins in focal adhesion formation (6, 7), but oligomerization mutants failed to enhance focal adhesion formation (Fig. 6A), reside in the Triton X-100-resistant cytoskeleton (Fig. 6B), interact with PKCa (Fig. 6D), or efficiently activate PKCa in vitro (Fig. 6E). This implies that transmembrane domain-induced oligomerization may control the biological activity of the syndecan-4 cytoplasmic domain. The syndecan-2 oligomerization mutant was also unable to regulate cell migration (Fig. 7). Therefore, it seems that the transmembrane domain is crucial for inducing functional oligomerization of the syndecan-2 and syndecan-4 core proteins. This is the first evidence to show the functionality of the transmembrane domain-induced oligomerization in vivo.

One of the most important observations in this study is the apparent specificity of the transmembrane domain. The functionality of the transmembrane domain is more significant when contrasted with growth factor receptor-mediated signal transduction. During transmembrane signaling, extracellular ligands bind to specific receptors on the cell surface, and the binding subsequently alters their oligomeric status to evoke a signal cascade inside the cell (9, 10). A variety of studies have shown that the activation of downstream signaling is dependent on the oligomeric status of the cytoplasmic domain. However, although it plays a major role in controlling oligomeric status of the cytoplasmic domain in the case of syndecans, the transmembrane domain has received relatively little attention. It is clear that oligomerization of the cytoplasmic domain of receptor is a different issue from that of whole receptor protein, where the transmembrane domains are a key driver of oligomerization. Thus, the transmembrane domain inevitably regulates the activity of the cytoplasmic domain and is crucial for receptor functions. How does the transmembrane domain regulate the cytoplasmic domain? Is it only by inducing oligomerization? Transmembrane domains of both PDGFR and syndecan are able to induce oligomerization of the receptor protein in vivo, although the ligand dependence may be different for the two. The important point is that they both have the potential to do so and that their oligomerization is crucial for activating signaling cascades. Interestingly, however, the unique nature of syndecan function is that the specific activity of syndecan requires the presence of syndecan but not of the PDGFR transmembrane domain. This is demonstrated by the syndecan/PDGFR chimeras where each syndecan transmembrane domain was substituted with that of PDGFR, which showed a clear defect in most of syndecan functions tested (Figs. 6 and 7). This implies that transmembrane domain-induced oligomerization is not just for aggregating the receptors. It may induce a quaternary structure of the cytoplasmic domain, whose overall structure is required for the specific function of each receptor protein. Therefore, syndecan transmembrane domain-induced oligomerization plays a syndecan-specific role in regulating the functions of syndecan that cannot be replaced by other transmembrane oligomerization domains. It remains unclear whether this is a general phenomenon of homo-oligomerization of receptors.

REFERENCES
1. Kim, C., Goldberger, O., Gallo, R., and Bernfield, M. (1994) Mol. Cell. Biol. 5, 797–805
2. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L., and Lose, E. J. (1992) Annu. Rev. Cell Biol. 8, 365–393
3. Carey, D. J. (1997) Biochem. J. 327, 1–16
4. Zimmermann, P., and David, G. (1999) FEBS J. 13, S91–S100
5. Rapraeger, A. C., and Ott, V. L. (1998) Curr. Opin. Cell Biol. 10, 620–628
6. Woods, A., and Couchman, J. R. (2001) Curr. Opin. Cell Biol. 13, 578–583
7. Rapraeger, A. C. (2000) J. Cell Biol. 149, 955–998
8. Simons, M., and Horowitz, A. (2001) Cell. Signal. 13, 855–862
9. Schlessinger, J. (2000) Cell 103, 211–225
10. Heldin, C. H. (1995) Cell 80, 213–223
11. Schlesinger, T. K., Demali, K. A., Johnson, G. L., and Kazlauskas, A. (1999) Biochem. J. 344, 519–526
12. DeMali, K. A., Balscianule, E., and Kazlauskas, A. (1999) J. Biol. Chem. 274, 19551–19558
13. Woods, A., and Couchman, J. R. (1994) Mol. Cell. Biol. 5, 183–192
14. Oh, E. S., Woods, A., and Couchman, J. R. (1997) J. Biol. Chem. 272, 8133–8136
15. Oh, E. S., Woods, A., Lim, S. T., Theibert, A., and Couchman, J. R. (1998) J. Biol. Chem. 273, 10624–10629
16. Horowitz, A., and Simons, M. (1998) J. Biol. Chem. 273, 10914–10918
17. Baci, P. C., and Goetinck, P. F. (1995) Mol. Biol. Cell 6, 1503–1513
18. Horowitz, A., Murakami, M., Gao, Y., and Simons, M. (1999) Biochemistry 38, 15871–15877
19. Asundi, V. K., and Carey, D. J. (1995) J. Biol. Chem. 270, 26404–26410
20. Imagaki, M., Watanabe, M., and Hidaka, H. (1985) J. Biol. Chem. 260, 2922–2925
21. Womerow, P., and Watson, S. P. (2001) Oncogene 20, 6273–6283
22. Tomilinson, M. G., Lin, J., and Weiss, A. (2000) Immuno. Today 21, 584–591
23. Longley, R., Woods A., Fleetwood A., Cowling G. J., Gallagher T. J., and Couchman J. R. (1999) J. Cell Sci. 112, 3421–3431
24. Echtermeyer, F., Baci, P. C., Saoucella, S., Ge, Y., and Goetinck, P. F. (1999) J. Cell Sci. 112, 3433–3441
25. Greene, D. K., Turnova, S., Couchman, J. R., and Woods A. (2003) J. Biol. Chem. 278, 7617–7623
26. Grootscholten, J. J., Zimmermann, P., Reekmans, G., Smets, A., Degeest, G., Durr, J., and David, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13683–13688
27. Grootscholten, J. J., Reekmans, G., Ceulemans, H., and David, G. (2000) J. Biol. Chem. 275, 19933–19941
28. Oh, E. S., and Couchman, J. R. (2004) Mol Cells 17, 181–187
Transmembrane Domain-induced Oligomerization Is Crucial for the Functions of Syndecan-2 and Syndecan-4
Sungmun Choi, Eunjung Lee, Soojin Kwon, Haein Park, Jae Youn Yi, Seungin Kim, Inn-Oc Han, Yungdae Yun and Eok-Soo Oh

J. Biol. Chem. 2005, 280:42573-42579.
doi: 10.1074/jbc.M509238200 originally published online October 27, 2005

Access the most updated version of this article at doi: 10.1074/jbc.M509238200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 25 references, 14 of which can be accessed free at http://www.jbc.org/content/280/52/42573.full.html#ref-list-1